LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 90 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $59,000 | -38.5% | 24,000 | -36.8% | 0.01% | -41.2% |
| Q3 2021 | $96,000 | -11.1% | 38,000 | 0.0% | 0.02% | -15.0% |
| Q2 2021 | $108,000 | +575.0% | 38,000 | +442.9% | 0.02% | +400.0% |
| Q1 2021 | $16,000 | +33.3% | 7,000 | 0.0% | 0.00% | +33.3% |
| Q4 2020 | $12,000 | – | 7,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,005,379 | $28,160,000 | 3.29% |
| Defender Capital, LLC. | 4,416,590 | $3,657,000 | 2.67% |
| Prescott General Partners LLC | 1,851,851 | $1,534,000 | 0.13% |
| Laidlaw Wealth Management LLC | 107,379 | $89,000 | 0.06% |
| Northeast Financial Consultants Inc | 523,756 | $434,000 | 0.05% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $37,000 | 0.04% |
| DAFNA Capital Management LLC | 95,000 | $79,000 | 0.03% |
| Summit X, LLC | 30,700 | $25,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 529,039 | $438,000 | 0.01% |
| Keudell/Morrison Wealth Management | 10,105 | $8,000 | 0.01% |